Mass spectrometry in clinical proteomics - from the present to the future

被引:66
|
作者
Palmblad, Magnus [3 ]
Tiss, Ali [1 ,2 ]
Cramer, Rainer [1 ,2 ]
机构
[1] Univ Reading, Bioctr, Reading RG6 6AS, Berks, England
[2] Univ Reading, Dept Chem, Reading RG6 6AS, Berks, England
[3] Leiden Univ, Biomol Mass Sepctrometry Unit, Dept Parasitol, Med Ctr, Leiden, Netherlands
关键词
Clinical proteomics; Diagnostics; Mass spectrometry; Profiling; Screening; LASER-DESORPTION/IONIZATION-TIME; NIPPLE ASPIRATE FLUID; SELDI-TOF-MS; PROTEIN IDENTIFICATION TECHNOLOGY; DIFFERENCE GEL-ELECTROPHORESIS; MALIGNANT MAMMOGRAPHIC LESIONS; SERUM PEPTIDOME PATTERNS; HUMAN PLASMA PROTEOME; BREAST-CANCER; OVARIAN-CANCER;
D O I
10.1002/prca.200800090
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
MS is an important analytical tool in clinical proteomics, primarily in the disease-specific discovery identification and characterisation of proteomic biomarkers and patterns. MS-based proteomics is increasingly used in clinical validation and diagnostic method development. The latter departs from the typical application of MS-based proteomics by exchanging some of the high performance of analysis for the throughput, robustness and simplicity required for clinical diagnostics. Although conventional MS-based proteomics has become an important field in clinical applications, some of the most recent MS technologies have not yet been extensively applied in clinical proteomics. in this review, we will describe the current state of MS in clinical proteomics and look to the future of this field.
引用
收藏
页码:6 / 17
页数:12
相关论文
共 50 条
  • [21] The Increasing Role of Mass Spectrometry in Quantitative Clinical Proteomics
    Whiteaker, Jeffrey R.
    CLINICAL CHEMISTRY, 2010, 56 (09) : 1373 - 1374
  • [22] Mass spectrometry for translational proteomics: progress and clinical implications
    Erin Shammel Baker
    Tao Liu
    Vladislav A Petyuk
    Kristin E Burnum-Johnson
    Yehia M Ibrahim
    Gordon A Anderson
    Richard D Smith
    Genome Medicine, 4
  • [23] Mass spectrometry-based clinical proteomics - a revival
    Pauwels, Jarne
    Gevaert, Kris
    EXPERT REVIEW OF PROTEOMICS, 2021, 18 (06) : 411 - 414
  • [24] Mass spectrometry based proteomics, background, status and future needs
    Peter Roepstorff
    Protein & Cell, 2012, 3 (09) : 641 - 647
  • [25] Mass spectrometry based proteomics, background, status and future needs
    Roepstorff, Peter
    PROTEIN & CELL, 2012, 3 (09) : 641 - 647
  • [26] Clinical proteomics and mass spectrometry profiling for cancer detection
    Solassol, Jerome
    Jacot, William
    Lhermitte, Ludovic
    Boulle, Nathalie
    Maudelonde, Thierry
    Mange, Alain
    EXPERT REVIEW OF PROTEOMICS, 2006, 3 (03) : 311 - 320
  • [27] Mass-spectrometry-based proteomics: from single cells to clinical applications
    Guo, Tiannan
    Steen, Judith A.
    Mann, Matthias
    NATURE, 2025, 638 (8052) : 901 - 911
  • [28] Recent advances in clinical proteomics using mass spectrometry
    Dowling, Paul
    Meleady, Paula
    Henry, Michael
    Clynes, Martin
    BIOANALYSIS, 2010, 2 (09) : 1609 - 1615
  • [29] Quantitative phosphoproteomics by mass spectrometry: Past, present, and future
    Nita-Lazar, Aleksandra
    Saito-Benz, Hideshiro
    White, Forest M.
    PROTEOMICS, 2008, 8 (21) : 4433 - 4443
  • [30] Postionization Mass Spectrometry Imaging: Past, Present, and Future
    Guan, Xiaokang
    Lu, Qiao
    Liu, Shuxian
    Yan, Xiaowen
    MASS SPECTROMETRY REVIEWS, 2024,